Recombinant human granulocyte-macrophage colony-stimulating factor after combined chemotherapy in high-grade non-Hodgkin's lymphoma--a randomised pilot study.

[1]  T. Chisesi,et al.  MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Matthews,et al.  Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Shipp.  Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high-risk" disease? , 1994, Blood.

[4]  Zuckerman Ks.  Efficacy of intensive, high-dose anthracycline-based therapy in intermediate- and high-grade non-Hodgkin's lymphomas. , 1994 .

[5]  R. Holle,et al.  Randomised comparison of CHOEP versus alternating hCHOP/IVEP for high-grade non-Hodgkin's lymphomas: treatment results and prognostic factor analysis in a multi-centre trial. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  C. de Wolf‐Peeters,et al.  EORTC study of non-Hodgkin's lymphoma: phase III study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphoma. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  G. Salles,et al.  Chemotherapy of non-Hodgkin's aggressive lymphomas. , 1994, Seminars in hematology.

[8]  D. Crowther,et al.  Haemopoietic growth factor and dose intensity in high-grade and intermediate-grade lymphoma. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  G. Canellos.  Critical review of the role of hemopoietic growth factors in dose intensification and outcome in the treatment of non-Hodgkin's lymphoma. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  L. Bergmann,et al.  [Pleomorphic T-cell lymphoma. The diagnostic problems, therapeutic possibilities and infection-induced complications]. , 2008, Deutsche Medizinische Wochenschrift.

[11]  K. Zuckerman,et al.  Chemotherapy of intermediate- and high-grade non-Hodgkin's lymphomas with an intensive epirubicin-containing regimen , 1993 .

[12]  J. Neidhart.  Hematopoietic cytokines current use in cancer therapy , 1993, Cancer.

[13]  J. Spinelli,et al.  Allogeneic bone marrow transplantation for poor-prognosis non-Hodgkin's lymphoma. , 1993, Bone marrow transplantation.

[14]  M. Engelhard,et al.  Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas [see comments] , 1993 .

[15]  M. Petrini,et al.  Third generation chemotherapy with P-VABEC for aggressive non-Hodgkin's lymphomas of the elderly. , 1993, Leukemia & lymphoma.

[16]  C Sebban,et al.  Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte). , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  J. Armitage,et al.  Role of autologous bone marrow transplantation in non-Hodgkin's lymphoma. , 1993, Hematology/Oncology Clinics of North America.

[18]  T M Grogan,et al.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[19]  J. Armitage,et al.  Treatment of non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[20]  B. Parker,et al.  AMOPLACE treatment of intermediate-grade and high-grade malignant lymphoma: a Cancer and Leukemia Group B study. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Bronchud.  The importance of dose: lymphomas as a model of chemosensitive malignancies. , 1993, European journal of cancer.

[22]  C. Sakai,et al.  A comparative study of CHOP versus MEVP (mitoxantrone, etoposide, vindesine, prednisolone) therapy for intermediate-grade and high-grade non-Hodgkin's lymphoma: a prospective randomized study. , 1993, International journal of hematology.

[23]  Clark Da,et al.  Granulocyte-macrophage colony-stimulating factor with dose-intensified treatment of cancer. , 1992 .

[24]  A. Romano,et al.  CEOP/PEB alternating chemotherapy in advanced intermediate and high-grade non-Hodgkin's lymphomas. , 1992, Haematologica.

[25]  C. Bennett,et al.  Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease. , 1992, Annals of internal medicine.

[26]  K. Bross,et al.  Cyclic alternating chemotherapy of high-grade malignant non-Hodgkin lymphomas with VIM-Bleo and CHOP. , 1992, European journal of cancer.

[27]  M. Kris,et al.  Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer , 1991 .

[28]  H. Dohy,et al.  Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. , 1990, The New England journal of medicine.

[29]  D Faraggi,et al.  Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables , 1990, Cancer.

[30]  G. Bonadonna,et al.  Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  J. Cebon,et al.  Characterization of the clinical effects after the first dose of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor. , 1989, Blood.

[32]  B. Coiffier,et al.  LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  A. Burgess,et al.  Effects of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy. , 1989, Annals of internal medicine.

[34]  M. Socinski,et al.  Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. , 1988, The New England journal of medicine.

[35]  D. Metcalf.  Granulocyte-macrophage colony-stimulating factors , 1985, Science.

[36]  E. Brown,et al.  Human GM-CSF: molecular cloning of the complementary DNA and purification of the natural and recombinant proteins. , 1985, Science.

[37]  Prof. Dr. Dr. h.c. mult. Karl Lennert,et al.  Histopathologie der Non-Hodgkin-Lymphome , 1981, Springer Berlin Heidelberg.

[38]  M Tubiana,et al.  Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.